On November 16, INSILICO fell 5.29% in Regular Trading, trading at HK$35.72, with turnover of HK$40.55 million.
The clearest catalyst in publicly available information is broad weakness across the Life Sciences Tools & Services sector, which appears to have outweighed company-specific positives including a recent share buyback and a new AI drug discovery partnership.
Company disclosures show INSILICO spent about HK$11.20 million on November 13 to repurchase 300,000 shares at HK$37.20 to HK$37.50 per share. On the same day, its wholly owned Shanghai unit signed a strategic cooperation agreement with Luoxin Pharmaceuticals to pursue AI-enabled drug discovery, initially focused on digestive diseases, metabolic disorders and other non-oncology chronic diseases.
However, sector trading was soft, with GENSCRIPT B-1K falling 2.77%, WUXI BIO falling 1.58%, WUXI APPTEC falling 1.51%, XTALPI falling 3.07%, and WUXI XDC falling 2.31%, reinforcing pressure on INSILICO despite those supportive announcements.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments